Canada's Eli Health secures $12m USD to bring saliva-based hormone tracking to market
World-first instant hormone monitoring system
A Canadian startup developing the world’s first instant hormone monitoring system has secured $12m in Series A funding, as interest grows in tools that offer women — and all individuals navigating hormone shifts — greater visibility into their own biology.
Eli Health is building what it describes as a “real-time interface to the human body.” Its lead product, the Hormometer™, offers rapid hormone testing using just a saliva sample and a smartphone.
With this latest funding round, led by BDC Capital’s Thrive Venture Fund, the company has now raised a total of $20m USD.
Largely inaccessible hormone monitoring
The launch of the Hormometer comes amid growing awareness of hormone health as a critical but often overlooked dimension of personal wellbeing. An estimated 60% of adults experience symptoms linked to hormonal imbalance, yet continuous monitoring remains largely inaccessible. Eli Health’s system seeks to change that — delivering results in minutes, without lab appointments or sample shipments.
The Hormometer's first target is cortisol, commonly known as the stress hormone. Cortisol levels naturally fluctuate across the day, peaking in the morning and falling in the evening. But that rhythm is easily disrupted by stress, poor sleep, irregular eating, light exposure and more. These fluctuations often go undetected by standard lab tests, which provide only a snapshot in time.
The company says progesterone will be the next biomarker to launch, and a waitlist is already open.
“Hormones regulate nearly every major system in the body — governing stress response, sleep, cognitive and physical performance, metabolism, immune function, and much more. But until now, this data has been largely invisible. It’s been too expensive, sporadic, and slow to offer the insight people need,” said Marina Pavlovic Rivas, Eli Health cofounder and CEO.
“We’ve created a real-time interface to the human body, where hormone tracking is as easy as checking your temperature and as quick as brushing your teeth. And now people will be able to use this data to guide daily decisions based on their body’s live feed.”
The platform is currently in private beta, with early adopters using it to integrate hormone tracking into their daily routines. Subscription plans start at $8 per test with a 12-month commitment.
The new funds will support manufacturing scale-up, the development of additional hormone markers, and broader access to the platform. The company’s technology, developed over five years, includes 12+ patent-pending innovations across biochemistry, hardware, software, AI, and endocrinology. The Hormometer has completed third-party validation, secured FDA registration, and is now manufactured in-house.
Earlier this year, Eli Health received the CES 2025 “Best of Innovation in Digital Health” award — an accolade recognising its potential to shape the future of personalised medicine.
Mona Minhas, partner at BDC’s Thrive Venture Fund and now a board member at Eli Health, praised the company’s foresight and execution.
“Hormonal health is rapidly emerging as one of the most important frontiers in personal wellness. Eli Health recognized this shift early. Through years of focused execution, they’ve built the science, technological platform, and manufacturing infrastructure to lead the category,” she said.
The Series A round includes participation from several high-profile investors such as Muse Capital, TELUS Global Ventures, Accelia Capital, and Real Ventures. Each cited the company’s ability to bridge the gap between consumer needs and clinical-grade health data.
“For the first time in history, we’ll have a continuous, real-world view of hormone patterns at scale,” said Assia Grazioli-Venier, Founding Partner at Muse Capital and Board Member at Eli Health.
“That kind of insight doesn’t just improve daily health, it redefines the very infrastructure of care.”
Annick Charbonneau, Founding Partner at Accelia Capital, echoed the sentiment.
“There’s a massive gap between today’s consumer health products and what people actually need to understand their bodies in real time. Eli Health closes that gap by fusing rigorous bioscience, custom microfluidic hardware, and a live data engine powered by computer vision into one seamless platform.”
This isn’t a single product—it’s the launchpad for a new class of everyday health and wellness tools. The technical depth and defensibility of their work are hard to overstate.”
With interest in personalised health surging — particularly among women navigating hormonal transitions such as perimenopause, fertility journeys, and chronic stress—Eli Health’s offering arrives at a critical moment. The company’s approach could eventually redefine how hormones are managed, tracked, and understood, not just by individuals but by healthcare systems.
The Hormometer is expected to publicly launch later this year.